Literature DB >> 25605650

CXCL10/IP-10 is a biomarker and mediator for Kawasaki disease.

Tai-Ming Ko1, Ho-Chang Kuo1, Jeng-Sheng Chang1, Shih-Ping Chen1, Yi-Min Liu1, Hui-Wen Chen1, Fuu-Jen Tsai1, Yi-Ching Lee1, Chien-Hsiun Chen1, Jer-Yuarn Wu2, Yuan-Tsong Chen2.   

Abstract

RATIONALE: Kawasaki disease (KD), an acute febrile vasculitis, is the most common cause of acquired heart disease in childhood; however, diagnosing KD can be difficult.
OBJECTIVE: To identify unique proteomic biomarkers that can be used to facilitate earlier diagnosis of KD. METHODS AND
RESULTS: We enrolled 214 children with fever and clinical features suggestive of KD. Of those, only 100 were diagnosed with KD. Their plasma samples were globally analyzed for cytokines, chemokines, and cell adhesion molecules using an unbiased, large-scale, quantitative protein array. This study was conducted in 3 stages: discovery, replication, and blinded validation. During the discovery phase (n [KD]=37; n [control]=20), the expression of interleukin-17F, sCD40L, E-selectin, CCL23 (myeloid progenitor inhibitory factor 1), and CXCL10 (IFN-γ-inducible protein 10 [IP-10]) were upregulated during the acute phase in patients with KD when compared with that in the controls. A notable increase was observed in the IP-10 levels (KD, 3037 ± 226.7 pg/mL; control, 672 ± 130.4 pg/mL; P=4.1 × 10(-11)). Receiver-operating characteristic analysis of the combined discovery and replication data (n [KD]=77; n [control]=77) showed that the IP-10 level had high area under the curve values (0.94 [95% confidence interval, 0.9055-0.9778]; sensitivity, 100%; and specificity, 77%). With 1318 pg/mL as the optimal cutoff, the blinded validation study confirmed that the IP-10 levels were a good predictor of KD. With intravenous immunoglobulin treatment, the IP-10 levels returned to normal. The downstream receptor of IP-10, CXCR3, was activated in the T cells of patients with acute KD.
CONCLUSIONS: IP-10 may be used as a biomarker to facilitate KD diagnosis, and it may provide clues about the pathogenesis of KD.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  IP-10; biomarkers; diagnosis; mucocutaneous lymph node syndrome; vasculitis

Mesh:

Substances:

Year:  2015        PMID: 25605650     DOI: 10.1161/CIRCRESAHA.116.305834

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  36 in total

1.  Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.

Authors:  Akira Hachiya; Norimoto Kobayashi; Satoshi Matsuzaki; Yusuke Takeuchi; Yohei Akazawa; Tomonari Shigemura; Noriko Motoki; Junya Masumoto; Kazunaga Agematsu
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

Review 2.  Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses.

Authors:  Nicholas W Mathy; Xian-Ming Chen
Journal:  J Biol Chem       Date:  2017-06-14       Impact factor: 5.157

Review 3.  The Roles of Genetic Factors in Kawasaki Disease: A Systematic Review and Meta-analysis of Genetic Association Studies.

Authors:  Xiaochuan Xie; Xiaohan Shi; Meilin Liu
Journal:  Pediatr Cardiol       Date:  2017-11-02       Impact factor: 1.655

4.  Interleukin-33/ST2 Axis as Potential Biomarker and Therapeutic Target in Kawasaki Disease.

Authors:  Seigo Okada; Hiroki Yasudo; Yuji Ohnishi; Chie Matsuguma; Reiji Fukano; Takahiro Motonaga; Takako Waniishi; Shunji Hasegawa
Journal:  Inflammation       Date:  2022-10-08       Impact factor: 4.657

5.  Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex.

Authors:  Aaron C Petrey; Fares Qeadan; Elizabeth A Middleton; Irina V Pinchuk; Robert A Campbell; Ellen J Beswick
Journal:  J Leukoc Biol       Date:  2020-09-15       Impact factor: 4.962

6.  Markedly elevated CD64 expression on neutrophils and monocytes as a biomarker for diagnosis and therapy assessment in Kawasaki disease.

Authors:  Sho Hokibara; Norimoto Kobayashi; Keiko Kobayashi; Tomonari Shigemura; Haruo Nagumo; Masahiro Takizawa; Takashi Yamazaki; Kazunaga Agematsu
Journal:  Inflamm Res       Date:  2016-03-28       Impact factor: 4.575

Review 7.  Chemokines in rheumatic diseases: pathogenic role and therapeutic implications.

Authors:  Yoshishige Miyabe; Jeffrey Lian; Chie Miyabe; Andrew D Luster
Journal:  Nat Rev Rheumatol       Date:  2019-11-08       Impact factor: 20.543

8.  High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.

Authors:  Sarah M McAlpine; Sarah E Roberts; John J Heath; Fabian Käsermann; Andrew C Issekutz; Thomas B Issekutz; Beata Derfalvi
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

Review 9.  Epigenetics in Kawasaki Disease.

Authors:  Kaushal Sharma; Pandiarajan Vignesh; Priyanka Srivastava; Jyoti Sharma; Himanshi Chaudhary; Sanjib Mondal; Anupriya Kaur; Harvinder Kaur; Surjit Singh
Journal:  Front Pediatr       Date:  2021-06-25       Impact factor: 3.418

10.  Comparison of Simplified Creatinine Index and Systemic Inflammatory Markers for Nutritional Evaluation of Hemodialysis Patients.

Authors:  Ming-Tsun Tsai; Wei-Cheng Tseng; Shuo-Ming Ou; Kuo-Hua Lee; Chih-Yu Yang; Der-Cherng Tarng
Journal:  Nutrients       Date:  2021-05-30       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.